Skip to main content

The European Prevention of Alzheimer's Dementia consortium (EPAD) is recruiting people to expand their knowledge about the preclinical Alzheimer's phase and to be able to carry out an adaptive clinical trial. This test will try different treatment areas at the same time, and will allow the rapid removal of drugs that do not show positive results, as well as introducing new ones. In the essay 1,500 people from all over Europe will participate.

EPAD is funded by subsidy nº 115736 of the Innovative Medicines Initiative, which is a joint initiative of the European Commission's Research and Innovation program Horizon 2020 and the European Federation of Pharmaceutical Industries and Associations (EFPIA).



European Prevention of Alzheimer’s Dementia consortium (EPAD)
EPAD will select participants to take part in streamlined proof-of-concept trials